Frameshift mutations in genes containing mononucleotide repeats are often observed in cancers exhibiting a high frequency of microsatellite instability (MSI-H). Several tumor types, including colorectal, gastric, and endometrial carcinomas, display this phenotype in a signi®cant proportion of cases. We recently showed in a large series of MSI-H colorectal tumors that approximately 40% of them exhibited frameshift mutations in an (A)9 tract within the coding region of the TCF-4 gene, a crucial member of the APC/b-catenin/TCF pathway. In the present study, we have examined MSI-H cancers from other primary tumor sites for mutations in this new target gene. Two of 22 (9%) MSI-H primary gastric cancers and none of 23 MSI-H endometrial primary tumors and cell lines were found to have a 1 bp deletion in the TCF-4 repeat. In the same series of tumors we also looked for frameshift mutations in other coding repeats localized within the TGFb-RII, BAX, IGFIIR, hMSH3 and hMSH6 genes. Our results suggest that the TCF-4 gene, in a similar manner to some of these latter genes, is dierentially altered in MSI-H tumors from dierent primary sites.
Keywords: TCF-4; coding repeat; stomach; endometrium; colon; microsatellite instability Cancers of the mutator phenotype (MSI-H) comprise a subset of tumors occurring at various primary sites. They accumulate frequent deletions and insertions in microsatellite DNA sequences due to de®cient repair of spontaneous errors which occur during the replication of these repetitive DNA sequences Thibodeau et al., 1993; Ionov et al., 1993) . The MSI-H phenotype is associated with the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome as a result of predisposing constitutional mutations in genes involved in DNA mismatch repair (Bronner et al., 1994; Papadopoulos et al., 1994; Fishel et al., 1993; Leach et al., 1993) . The MSI-H phenotype is also observed in about 15% of sporadic colon, gastric and endometrial carcinomas. Underlying genetic mechanisms of carcinogenesis in tumors showing microsatellite instability are believed to involve frameshift mutations in target genes which contain coding repeat sequences. Some of these, including the TGFb-RII, BAX and IGFIIR genes are mutated in a signi®cant proportion of MSI-H cancers Souza et al., 1996; Rampino et al., 1997) . Frameshift mutations in the MSH3 and MSH6 DNA repair genes have also been reported (Malkhosyan et al., 1996) .
Recently we showed that the TCF-4 gene, a crucial member of the APC/b-catenin/TCF pathway, was also frequently mutated in an (A)9 coding repeat in MSI-H colorectal cancer cell lines and primary tumors (Duval et al., 1999) . This has now been extended to a total of 104 samples of which 35 (33.5%) showed a 1 bp deletion in this repeat. TCF-4 is a transcription factor which upregulates expression of c-MYC (He et al., 1998) as well as the expression of several other genes when complexed with b-catenin Morin et al., 1997) . Due to its high frequency of mutation, we have proposed that this deletion event is selected for and plays an important role in MSI-H colorectal carcinogenesis (Duval et al., 1999) .
The aim of the present work was to analyse the prevalence of mutation in the TCF-4 (A)9 coding repeat in gastric and endometrial MSI-H tumors. Twenty-two gastric and 19 endometrial MSI-H primary tumors were selected from larger series. The MSI status of part of these tumors was established by comparing the pro®les of PCR-ampli®ed dinucleotide microsatellites in tumor DNA and matching normal DNA. All of them were con®rmed to be MSI-H by using the mononucleotide repeats BAT-26 in intron 5 of h-MSH2 and BAT-25 in intron 16 of c-kit . These markers have been shown to establish MSI status with an accuracy of greater than 99.5% (Hoang et al., 1997; Zhou et al., 1998) . Twelve gastric and 24 endometrial non-MSI tumors were also analysed as controls. Moreover, four MSI-H endometrial cancer cell lines (HEC-59, Ishikawa, RL95-2 and HEC1-A) obtained from Dr F Vignon (INSERM U148, Montpellier, France) were included in the analysis.
Template DNA from each tumor was ampli®ed by PCR using primers P40S and P40AS (Duval et al., 1999) to look for mutations in the (A)9 coding repeat of the TCF-4 gene. The PCR products were run on a denaturing polyacrylamide gel, transferred to a nylon membrane and hybridized with the P22AS 32 P-labeled probe as described (Duval et al., 1999) .
The (A)9 repeat was mutated in two out of 22 gastric MSI-H tumors (9%) but in none of 23 MSI-H endometrial cancers and cell lines (Figure 1 ). As expected, no mutations were found in the 36 non-MSI tumor samples (data not shown). TCF-4 mutations in the two gastric tumor samples were con®rmed by DNA sequencing (Figure 2) . In both cases, one A was deleted in the (A)9 repeat. Because of contaminating normal cells, it was not possible to determine whether these mutations were homozygous or heterozygous in nature.
Thus, dierent frequencies of frameshift mutations are observed in the TCF-4 coding repeat in colorectal, gastric and endometrial MSI-H tumors ( Table 1 ). The prevalence of these mutations in colorectal tumors (35/ 104=33.5%) is signi®cantly dierent to that observed in gastric and endometrial tumors (P=0.0001, Fisher's exact test).
It has already been reported that other genes containing coding repeats may be mutated at different frequencies in MSI-H tumors arising from dierent primary sites. This has been shown notably for the TGFb-RII gene which is mutated in 70 ± 90% of MSI-H gastric and colorectal tumors but in only 17% of endometrial MSI-H tumors Myero et al., 1995) . For other genes probably involved in tumoral progression (BAX, IGFIIR) or implicated in the mismatch repair process (MSH3, MSH6) the published results are not as clear. Reported mutation frequencies for each of them vary considerably from one study to another, as exampli®ed by the BAX coding repeat reported to be mutated in 16 out of 25 cases or in two out of 13 cases (Wu et al., 1998) of gastric MSI-H tumors respectively.
Besides ethnic dierences and the small sizes of most tumor series analysed to date, several other factors could contribute to the observed discrepancies. The criteria used to de®ne the MSI status of tumors may not be the same in dierent studies and it is known that MSI misclassi®cation can be frequent. Moreover, 1 bp insertions and deletions in coding repeats are generally detected by denaturing gel electrophoresis of PCR products. Because of artefactual Taq polymerase errors which occur during PCR, small size alterations of PCR products are dicult to detect, particularly in primary tumors which contain signi®cant amounts of contaminating normal tissue. Results are often quite borderline and thus the mutation frequency of a particular gene may vary from one study to another. For these reasons, size variations of ®ve coding repeats located within the TGFb-RII, BAX, IGFIIR, MSH3, and MSH6 genes were studied in our series of unambiguous MSI-H gastric and endometrial tumors and in a subset of MSI-H colorectal tumors. Even if we are not completely sheltered from misinterpretation, we believe that our results may be more comparable to each other since we used the same tumors from three dierent primary sites and the same methodology to study these ®ve target genes (Table 1) .
No signi®cant dierences were observed in mutation frequencies for the IGFIIR, BAX, MSH3 and MSH6 genes between MSI-H tumors from various primary sites. In contrast, we con®rmed that the (A)10 coding repeat in TGFb-RII was signi®cantly more often mutated in colorectal and gastric MSI-H cancers than in endometrial cancers (P=0.0001).
In MSI-H colon cancers, mutations of the (A)9 repeat in the TCF-4 gene are relatively frequent. We have proposed that this mutation modi®es the respective proportion of various TCF-4 isoforms, and therefore has a potential role in regulating TCF-4 transactivating properties (Duval et al., 1999) . Moreover, mutations of the APC and b-catenin genes in the same pathway are frequent in colorectal cancers. These observations support the proposal that TCF-4 is a genuine target gene for microsatellite instability in colonic tumors.
Since no mutations were found in TCF-4 in a series of 23 MSI-H endometrial carcinomas it can be concluded that it is not a target for deletion/ insertion in this tumor type. This may be related to the fact that APC gene mutations have not yet been reported and that b-catenin alterations are not frequent in endometrial cancers (Fukuchi et al., 1998) .
Gastric MSI-H cancers have a low frequency (9%) of TCF-4 mutations and therefore it is unclear whether they are of functional signi®cance in this tumor type. Beta-catenin is not mutated in gastric carcinomas (Candidus et al., 1996) and APC mutations have been reported to occur at a low frequency in some studies Horii et al., 1992) and not at all in another one . Thus, mutations in genes of the APC/bcatenin/TCF pathway could be a rare event in gastric tumors. Therefore, frameshift mutations within the TCF-4 coding repeat may simply be a bystander event.
In this work, we have presented evidence that another frequent target gene for instability, TCF-4, was mutated with signi®cant dierent frequencies in MSI-H tumors from various primary sites. Thus, target genes in MSI-H tumors can be classi®ed into those which are mutated irrespective of the primary site such as BAX and IGFIIR, and those such as TGFbRII and TCF-4 which show signi®cant dierences in their mutation frequencies depending on the primary tumor site. The latter may be due to the existence of dierent tumorigenic pathways implicated at each of the various sites.
